We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Alnylam Pharmaceuticals, ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Medicines and Healthcare products Regulatory Agency ...

Alnylam (Nasdaq: ALNY) has secured expanded UK regulatory approval for Amvuttra (vutrisiran), broadening its indication to include treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in adults ...

Amvuttra’s approval with a broad label that includes language about reducing cardiovascular mortality and urgent heart failure visits positions it favorably against competitors.

Medically reviewed by Christopher Lee, MD Treatment for ATTR-CM has historically been symptom management. However, until 2019, the United States Food and Drug Administration (FDA) did not approve any ...

The AI model effectively spotted all subtypes of amyloidosis in the dataset, with an area under the receiver-operating characteristic curve (AUROC) of 0.93, a sensitivity of 85% for identifying ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $357.7, a high estimate of $404.00, and a low estimate of $325.00. Marking an increase of 10.61%, the ...

Additionally, Alnylam reiterated its 2025 total product revenue guidance of $2.05-2.25 billion during a recent meeting with Needham, which raised its price target for Alnylam to $377.00, maintaining a ...

The recent entry of Amvuttra into the market has raised concerns about its impact on Attruby’s uptake rate.

The recent entry of Amvuttra into the market has raised concerns about its impact on Attruby’s uptake rate. Additionally, the potential for genericization of existing treatments like tafamidis could ...

Sequoia Financial Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 3.0% in the first quarter, HoldingsChannel reports. The fund owned 3,395 ...